LGC Clinical Diagnostics Acquires Urinalysis Quality Controls Provider Kova International

LGC Clinical Diagnostics (Middlesex, UK), a business unit of LGC and a leading provider of biological materials and viral antigens, has acquired Kova International, Inc. (Garden Grove, CA, USA), a developer and manufacturer of in vitro urinalysis and toxicology quality control products for clinical laboratories. Kova has two manufacturing facilities, one focusing on urinalysis quality controls and the other on toxicology quality controls. Both the manufacturing facilities are certified to ISO 13485:2016 quality management system standards and guidelines, as well as cGMP qualified to manufacture quality control products, and are registered FDA manufacturing sites for the clinical diagnostic laboratory industry.

Kova’s quality control products are employed in hospitals, employee wellness programs, forensic testing and medical device manufacturers production and Quality Assurance (QA) programs. The acquisition expands LGC Clinical Diagnostics’ clinical quality control portfolio, complementing its wide range of offerings across biochemistry, serology, molecular, and clinical genomics quality controls and reference materials. LGC Clinical Diagnostics has over 35 years of industry experience and caters to more than 20,000 customers in over 100 counties. The company is keen on combining Kova’s expertise with its own in order to offer its customers unmatched solutions with expanded capabilities.

“We are excited to bring Kova’s established clinical urinalysis and toxicology quality controls into LGC Clinical Diagnostics,” said Bharathi Anekella, Executive Vice President & General Manager of LGC Clinical Diagnostics. “Kova and LGC Clinical Diagnostics are an excellent fit. Our focus on delivering confidence to clinical laboratories in test precision, accuracy, and conformance to international standards, perfectly aligns us with a common objective of Science for a Safer World.”

Related Links:
LGC
Kova International, Inc.